Premature Ovarian Insufficiency - Hormone Replacement Therapy and Management of Long-term Consequences

Overview

Journal Prz Menopauzalny

Publisher Termedia

Date 2018 Oct 26

PMID 30357030

Citations 12

Authors

Paulina Machura

Monika Grymowicz

Ewa Rudnicka

Wojciech Pieta

Anna Calik-Ksepka

Jolanta Skorska

Roman Smolarczyk

Affiliations

Soon will be listed here.

Abstract

Premature ovarian insufficiency (POI) correlates with increased risk of cardiovascular diseases, osteoporosis, genitourinary syndrome, and other symptoms of prolonged oestrogen deprivation. Properly selected therapy improves the quality of women's lives and reduces the risk of mortality. There is a wide spectrum of available oestrogen and progestogen formulations restoring proper levels of serum sex steroid hormones. The treatment should be implemented at recognition of the POI and continued to at least the age of natural menopause. Transdermal oestradiol and oral or vaginal progesterone administration provide the most physiological sex steroid replacement therapy. Patients' views and individual preference according the route, dose, and regimen of hormonal treatment have to be taken into consideration in order to achieve high compliance rates. Women with POI should be managed by a multidisciplinary team, such as a gynaecologist, endocrinologist, dietitian, and psychologist.

Citing Articles

A global bibliometric and visual analysis of research on premature ovarian failure: Based on the perspective of stem cells.

Xu Z, Zhu Y, Liu L, Liu C, Dong Z Medicine (Baltimore). 2024; 103(22):e38399.

PMID: 39259078 PMC: 11142804. DOI: 10.1097/MD.0000000000038399.

Research Progress on the Etiology and Treatment of Premature Ovarian Insufficiency.

Wang Y, Jiang J, Zhang J, Fan P, Xu J Biomed Hub. 2023; 8(1):97-107.

PMID: 38094192 PMC: 10718577. DOI: 10.1159/000535508.

Cardiovascular Risk Factors in Premature Ovarian Insufficiency using Hormonal Therapy.

Pravatta Rezende G, Dassie T, Angerame Yela Gomes D, Benetti-Pinto C Rev Bras Ginecol Obstet. 2023; 45(6):312-318.

PMID: 37494573 PMC: 10371067. DOI: 10.1055/s-0043-1770088.

Potential Therapeutic Options for Premature Ovarian Insufficiency: Experimental and Clinical Evidence.

Ding X, Lv S, Guo Z, Gong X, Wang C, Zhang X Reprod Sci. 2023; 30(12):3428-3442.

PMID: 37460850 DOI: 10.1007/s43032-023-01300-1.

Live birth in woman with premature ovarian insufficiency and 46, XY karyotype after chemotherapy and bone marrow transplant: a case report.

Zhang Y, Wang H, Pan X BMC Pregnancy Childbirth. 2023; 23(1):170.

PMID: 36915065 PMC: 10012704. DOI: 10.1186/s12884-023-05464-1.

References

Guerrieri G, Martinez P, Klug S, Haq N, Vanderhoof V, Koziol D . Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. Menopause. 2014; 21(9):952-61. PMC: 4112175. DOI: 10.1097/GME.0000000000000195. View

Martyn-St James M, Carroll S . Meta-analysis of walking for preservation of bone mineral density in postmenopausal women. Bone. 2008; 43(3):521-31. DOI: 10.1016/j.bone.2008.05.012. View

Soni M, Hogervorst E . Premature ovarian insufficiency and neurological function. Minerva Endocrinol. 2014; 39(3):189-99. View

Jankowska K . Premature ovarian failure. Prz Menopauzalny. 2017; 16(2):51-56. PMC: 5509972. DOI: 10.5114/pm.2017.68592. View

Bachelot A, Nicolas C, Gricourt S, Dulon J, Leban M, Golmard J . Poor Compliance to Hormone Therapy and Decreased Bone Mineral Density in Women with Premature Ovarian Insufficiency. PLoS One. 2016; 11(12):e0164638. PMC: 5132216. DOI: 10.1371/journal.pone.0164638. View

Vujovic S, Brincat M, Erel T, Gambacciani M, Lambrinoudaki I, Moen M . EMAS position statement: Managing women with premature ovarian failure. Maturitas. 2010; 67(1):91-3. DOI: 10.1016/j.maturitas.2010.04.011. View

Torrealday S, Kodaman P, Pal L . Premature Ovarian Insufficiency - an update on recent advances in understanding and management. F1000Res. 2017; 6:2069. PMC: 5710309. DOI: 10.12688/f1000research.11948.1. View

Faubion S, Kuhle C, Shuster L, Rocca W . Long-term health consequences of premature or early menopause and considerations for management. Climacteric. 2015; 18(4):483-91. PMC: 4581591. DOI: 10.3109/13697137.2015.1020484. View

Maclaran K, Panay N . Current concepts in premature ovarian insufficiency. Womens Health (Lond). 2015; 11(2):169-82. DOI: 10.2217/whe.14.82. View

10.

Gelbaya T, Vitthala S, Nardo L, Seif M . Optimizing hormone therapy for future reproductive performance in women with premature ovarian failure. Gynecol Endocrinol. 2010; 27(1):1-7. DOI: 10.3109/09513590.2010.501875. View

11.

Manolagas S, OBrien C, Almeida M . The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013; 9(12):699-712. PMC: 3971652. DOI: 10.1038/nrendo.2013.179. View

12.

Sassarini J, Lumsden M, Critchley H . Sex hormone replacement in ovarian failure - new treatment concepts. Best Pract Res Clin Endocrinol Metab. 2015; 29(1):105-14. DOI: 10.1016/j.beem.2014.09.010. View

13.

Fournier A, Berrino F, Clavel-Chapelon F . Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2007; 107(1):103-11. PMC: 2211383. DOI: 10.1007/s10549-007-9523-x. View

14.

Mishell Jr D, Nakamura R, Crosignani P, Stone S, Kharma K, Nagata Y . Serum gonadotropin and steroid patterns during the normal menstrual cycle. Am J Obstet Gynecol. 1971; 111(1):60-5. DOI: 10.1016/0002-9378(71)90927-6. View

15.

Pacello P, Yela D, Rabelo S, Giraldo P, Benetti-Pinto C . Dyspareunia and lubrication in premature ovarian failure using hormonal therapy and vaginal health. Climacteric. 2013; 17(4):342-7. DOI: 10.3109/13697137.2013.860116. View

16.

Kalantaridou S, Naka K, Papanikolaou E, Kazakos N, Kravariti M, Calis K . Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab. 2004; 89(8):3907-13. DOI: 10.1210/jc.2004-0015. View

17.

Suckling J, Lethaby A, Kennedy R . Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006; (4):CD001500. DOI: 10.1002/14651858.CD001500.pub2. View

18.

Langrish J, Mills N, Bath L, Warner P, Webb D, Kelnar C . Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension. 2009; 53(5):805-11. DOI: 10.1161/HYPERTENSIONAHA.108.126516. View

19.

Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B . ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016; 31(5):926-37. DOI: 10.1093/humrep/dew027. View

20.

Crofton P, Evans N, Bath L, Warner P, Whitehead T, Critchley H . Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol (Oxf). 2010; 73(6):707-14. DOI: 10.1111/j.1365-2265.2010.03868.x. View